SELLAS Life Sciences to Provide Third Quarter 2018 Financial Results and Corporate Update on November 15, 2018
November 08, 2018 08:45 ET
|
SELLAS Life Sciences Group
NEW YORK, Nov. 08, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq:SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel...
SELLAS Life Sciences Announces Positive Final Data in Triple Negative Breast Cancer Patients from Phase 2b Clinical Trial of Nelipepimut-S (NeuVax™) in Combination with Trastuzumab (Herceptin®) Presented at the European Society for Medical Oncology (ESMO) 2018 Annual Meeting
October 22, 2018 07:00 ET
|
SELLAS Life Sciences Group
Clinically and statistically significant efficacy in the triple negative breast cancer cohort with a p-value of 0.013 and a 75.2% reduction in risk of relapse or death in favor of investigational...
Data Safety Monitoring Board Confirms Triple Negative Breast Cancer as the Target Patient Population for Development of NeuVax™ (nelipepimut-S) in Combination with Trastuzumab (Herceptin®) in HER2 1+/2+ Breast Cancer Patients Following Final Analysis of Phase 2B Trial
October 19, 2018 08:05 ET
|
SELLAS Life Sciences Group
Data Safety Monitoring Board met on October 15, 2018 for final analysis Interim and final results of the Phase 2b study to be presented on Monday, October 22, 2018 during an oral presentation at the...
SELLAS to Host Conference Call Following Oral Presentation of Phase 2b Results of NeuVax™ + Herceptin® to Prevent Breast Cancer Recurrence at the European Society for Medical Oncology (ESMO) 2018 Annual Meeting
October 15, 2018 08:30 ET
|
SELLAS Life Sciences Group
Interim and Updated Final Clinical Data to be Presented Conference Call on October 22, 2018 at 8:00 a.m. ET NEW YORK, Oct. 15, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc....
SELLAS to Present Data from Phase 2b Trial of NeuVax + Herceptin® at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting
October 02, 2018 16:01 ET
|
SELLAS Life Sciences Group
NEW YORK, Oct. 02, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq:SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel...
SELLAS Life Sciences to Present at the 2018 Cantor Global Healthcare Conference
September 24, 2018 16:30 ET
|
SELLAS Life Sciences Group
NEW YORK, Sept. 24, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq:SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel...
SELLAS Receives Orphan Medicinal Product Designation Approval by the Committee for Orphan Medicinal Products of the European Medicines Agency for Galinpepimut-S for the Treatment of Patients with Multiple Myeloma
September 13, 2018 08:30 ET
|
SELLAS Life Sciences Group
NEW YORK, Sept. 13, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq:SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel...
SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2018 Financial Results
August 15, 2018 08:00 ET
|
SELLAS Life Sciences Group
NEW YORK, Aug. 15, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq:SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel...
SELLAS To Present Data from Phase 2b Trial of NeuVax + Herceptin® at Upcoming European Society for Medical Oncology (ESMO) 2018 Meeting
July 23, 2018 08:40 ET
|
SELLAS Life Sciences Group
Oral Presentation of NeuVax + Herceptin in the Adjuvant Treatment of Triple-Negative Breast Cancer Conference Scheduled for October 19-23, 2018 in Munich, Germany NEW YORK, July 23, 2018 (GLOBE...
SELLAS Receives Fast Track Designation from FDA for Galinpepimut-S for the Treatment of Patients with Multiple Myeloma
July 20, 2018 08:30 ET
|
SELLAS Life Sciences Group
NEW YORK, July 20, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group Inc. (Nasdaq:SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel...